Research Notes
Published 8 August 2026 · Obsidian BioTech Research Team
Retatrutide (developmental code LY3437943) is one of the most closely watched compounds in current metabolic research. Unlike single- or dual-receptor incretin analogues, it is designed to act on three receptor systems simultaneously — a pharmacological approach that has generated substantial interest in the peer-reviewed and clinical trial literature. This overview summarises what has been published so far.
Retatrutide is a triple receptor agonist, meaning it activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors in a single molecule. GLP-1 and GIP agonism are both established mechanisms in metabolic research, underlying several currently marketed and investigational compounds. The addition of glucagon receptor activity is what distinguishes triple agonists from dual GLP-1/GIP agonists — glucagon receptor signalling is associated with increased energy expenditure in preclinical models, layered on top of the appetite and glycaemic effects of GLP-1/GIP activation.
Retatrutide has progressed through Phase 2 trials into Phase 3 investigation, sponsored by Eli Lilly, primarily in the context of obesity and metabolic dysfunction research, with additional trial arms examining metabolic dysfunction-associated steatohepatitis (MASH). Published Phase 2 results reported dose-dependent effects on body weight over a 24–48 week trial period, along with changes in several cardiometabolic markers. As with any compound still in active trials, findings should be treated as provisional — Phase 3 data, safety profiling and regulatory review are still in progress at the time of writing.
Single-mechanism incretin therapies tend to plateau in efficacy at higher doses, and researchers have been exploring multi-receptor approaches specifically to address that ceiling. The rationale documented in the literature is that combining complementary mechanisms — appetite suppression and glycaemic control via GLP-1/GIP, additional energy expenditure via glucagon receptor activity — may produce effects beyond what any single pathway achieves alone. This is the same rationale that drove earlier development of dual GLP-1/GIP agonists, extended one step further.
Our Retatrutide is supplied as a 20mg lyophilised vial or pre-filled research pen, independently verified to >99% purity by HPLC. See our storage and reconstitution guide for correct handling once a vial is opened — reconstitution technique and cold-chain storage both materially affect compound stability over the course of a research project.
Research Use Only
This article summarises publicly available research and clinical trial literature for informational purposes only. It is not medical advice and does not describe an approved treatment. Retatrutide has not been approved by the MHRA, FDA or any regulatory body for human or veterinary use, and is supplied by Obsidian BioTech strictly for in-vitro laboratory research.
Related Products